Spotlight on rizatriptan in migraine

CNS Drugs

Volumn 16, Issue 10, 2002, Pages 715-720

  Wellington, Keri ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; ETHINYLESTRADIOL; FROVATRIPTAN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; MIGRAINE; NAUSEA; PAIN; PHOTOPHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOMNOLENCE; SYMPTOM; THORAX PAIN; VERTIGO;

EID: 0036398445     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216100-00005     Document Type: Review

References (35)

1. 1B/1D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 1997; 36 (4-5): 499-512
2. 1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55 (Suppl. 2): S8-14
3. 1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000; 68 (4): 418-26
4. 1D agonist. Br J Clin Pharmacol 1997; 43: 49-54
5. Sciberras DG, Majmudar N, Bowman AJ, et al. A study of the effects of MK-462 (rizatriptan), clonidine and sumatriptan on autonomic function. Br J Clin Pharmacol 1997; 43: 535P
6. 1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. J Clin Pharmacol 2000; 40 (1): 74-83
7. Noveck RJ, Bialy GP, Bradstreet TE, et al. Effects of rizatriptan on blood pressure in hypertensive patients. Clin Pharmacol Ther 1998 Feb; 63: 184
8. Williamson DJ, Hill RG, Shepheard SL, et al. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J PharmacoL 2001; 133 (7): 1029-34
9. Williamson DJ, Shepheard SL, Hill RG, et al. The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997; 328: 61-4
10. 1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001; 52 (1): 69-76
11. Merck and Co., Inc. Maxalt® and Maxalt-MLT® prescribing information: West Point, USA, 1998 [online]. Available from URL: http://www.merck.com [Accessed 2002 Mar 7]
12. Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999; 47: 373-8
13. Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos 2000; 28 (1): 89-95
14. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999; 39: 192-9
15. van Haarst AD, van Gerven JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48: 190-6
16. Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther 2001 Oct; 39 (10): 447-52
17. Shadle CR, Liu G, Goldberg MR. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J Clin Pharmacol 2000; 40 (3): 309-15
18. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine: the Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19: 525-30
19. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647-51
20. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study: the Rizatriptan 022 Study Group. Headache 1998 Apr; 38: 281-7
21. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine: the Rizatriptan 046 Study Group. Headache 1998 Nov-Dec; 38: 737-47
22. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine: the Rizatriptan 030 Study Group. Headache 1998 Nov-Dec; 38: 748-55
23. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks: the Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773-81
24. Lines C, Visser WH, Vandormael K, et al. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 1997 May; 37 (5): 319-20
25. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine: the Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000; 20 (5): 455-61
26. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine: the Rizatriptan-Naratriptan Study Group. Eur Neurol 1999; 42 (3): 173-9
27. Lipton RB, Pascual J, Goadsby PJ, et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache 2001; 41 (8): 754-63
28. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001 Oct; 57: 1377-83
29. Göbel H, Heinze A, Heinze-Kuhn K, et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. Headache 2001 Mar; 41 (3): 264-70
30. Cady R, Crawford G, Ahrens S, et al. Long-term efficacy and tolerability of rizatriptan wafers in migraine: the Rizatriptan-RPD Study Group. MedGenMed 2001 Jun 1; 3 (3): 1
31. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358 (9294): 1668-75
32. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001; 4: 105-25
33. Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine [abstract]. Obstet Gynecol 2000; 96 (2): 237-42
34. Silberstein SD, Massiou H, McCarroll KA, et al. Long-term efficacy of rizatriptan wafers in menstrual migraine. Cephalalgia 2001 May; 21: 423
35. Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs 1999 Oct; 58 (4): 699-723